Corps Capital Advisors LLC Buys Shares of 6,437 Johnson & Johnson (NYSE:JNJ)

Corps Capital Advisors LLC acquired a new stake in Johnson & Johnson (NYSE:JNJ) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 6,437 shares of the company’s stock, valued at approximately $931,000.

Other institutional investors have also modified their holdings of the company. Cumberland Partners Ltd boosted its stake in shares of Johnson & Johnson by 18.4% in the fourth quarter. Cumberland Partners Ltd now owns 18,300 shares of the company’s stock valued at $2,647,000 after purchasing an additional 2,850 shares during the period. Ieq Capital LLC lifted its holdings in Johnson & Johnson by 6.1% during the 4th quarter. Ieq Capital LLC now owns 154,698 shares of the company’s stock worth $22,372,000 after buying an additional 8,882 shares in the last quarter. Emerald Advisors LLC boosted its position in Johnson & Johnson by 2.5% in the 4th quarter. Emerald Advisors LLC now owns 3,091 shares of the company’s stock valued at $447,000 after buying an additional 75 shares during the period. Private Wealth Partners LLC grew its stake in shares of Johnson & Johnson by 3.4% in the fourth quarter. Private Wealth Partners LLC now owns 83,155 shares of the company’s stock worth $12,026,000 after acquiring an additional 2,728 shares in the last quarter. Finally, TBH Global Asset Management LLC increased its position in shares of Johnson & Johnson by 0.8% during the fourth quarter. TBH Global Asset Management LLC now owns 18,921 shares of the company’s stock worth $2,729,000 after acquiring an additional 142 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently commented on JNJ. Raymond James lowered their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Stifel Nicolaus lowered their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Finally, Leerink Partners decreased their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Trading Up 1.7 %

NYSE:JNJ opened at $162.35 on Friday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The stock’s 50 day moving average price is $148.93 and its 200 day moving average price is $155.88. The company has a market capitalization of $390.87 billion, a PE ratio of 24.41, a P/E/G ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the company posted $2.29 EPS. On average, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.06%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Insider Buying and Selling

In related news, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.